NADMED has closed a series A round to fund its entry into the U.S. and other international markets with its nicotinamide adenine dinucleotide (NAD) measurement technology that may help clinicians establish more precise and personalized treatments for various diseases.

The round was led by Finnish science-based startup investor Nordic Science Investments (NSI). Additional funding was secured from previous investors Voima Ventures and University of Helsinki Funds, from a number of private European investors, and a grant from Business Finland.

“In the coming years, metabolism will be the hottest topic in medicine and biology, especially when applied to personalized health and disease understanding. In this dawning age of metabolism, NAD will be the new DNA,” says Jari Närhi, CEO and co-founder at NADMED. “We are pleased and grateful for the funding from these insightful investors to spread and further develop the unique technology to measure all REDOX metabolites – something that was not possible before. This investment will enable us to bring new capabilities to diagnostics, therapy monitoring, personalized medicine, and advancement of metabolic science for the benefit of mankind.”

Read more: My Nordic Corner: Jari Närhi, CEO of NADMED

Each metabolite to be measured individually

NADMED’s key advantage is that its extraction method allows each metabolite to be measured individually, unlike any other method. Previously, mass spectrometry was the only available solution to accurately measure NAD+, but unable to measure reduced forms of NAD. Mass spectrometry is highly accurate but expensive and has low throughput and capacity. NADMED’s analysis has been validated against mass spectrometry. NADMED’s kits are the only CE-marked medical devices for NAD testing on the market.

“Investing in NADMED was a compelling choice for us, driven by the exceptional expertise of Professor Anu Suomalainen Wartiovaara, a globally recognized leader in metabolic disorders. For investors, the company’s diverse target market not only provides robust risk mitigation but also presents exciting growth opportunities across multiple sectors,” says Alexandra Gylfe, Founding Partner at NSI. “We are eager to leverage our strong U.S. science and biotech networks to support NADMED’s expansion into the U.S. market, enhancing their global footprint and driving further success in the years to come.”

NADMED currently serves customers in 27 countries, including clinical laboratories (e.g., Synlab), universities (e.g., Newcastle University), research institutions (e.g., NIH), and pharmaceutical companies (e.g., Clene Nanomedicine).

Photo of Jari Närhi: NADMED